Guerbet signs China distribution pact for Lipiodol

By staff writers

September 25, 2015 -- French contrast developer Guerbet has signed an agreement to promote and distribute its Lipiodol Ultra-Fluid liver contrast agent in China.

Guerbet signed the deal with pharmaceutical distributor and importer Beijing Keyuan Xinhai Pharmaceutical to distribute and commercialize Lipiodol.

Lipiodol was developed for diagnostic radiology applications, including liver lesion diagnosis, lymphography, and hysterosalpingography, and it is also used in interventional radiology as a contrast agent, a drug-eluting vehicle, and an arterioportal transient embolic, the company said.

Liver cancer is particularly prevalent in China due to the prevalence of viral hepatitis, Guerbet said.

Guerbet bids to buy Mallinckrodt's contrast business
French contrast agent developer Guerbet plans to acquire the contrast media and injector business of U.S. firm Mallinckrodt. The $270 million deal will...
FDA recognizes Guerbet for solving Ethiodol shortage
Guerbet has received recognition from the U.S. Food and Drug Administration for alleviating a drug shortage of its Ethiodol (ethiodized oil) contrast...
Sirtex and Guerbet to collaborate
Sirtex Medical and Guerbet are collaborating to advance research in the interventional treatment of primary and secondary metastatic liver cancer.
Guerbet takes aim at U.S. with launch of Dotarem MRI contrast
French contrast agent developer Guerbet isn't exactly a household name in the U.S., but the company hopes this will change with the launch this summer...
FDA approves Guerbet's Dotarem MRI contrast
French contrast developer Guerbet has received approval for its Dotarem (gadoterate meglumine) MRI contrast agent from the U.S. Food and Drug Administration.

Copyright © 2015

Last Updated np 9/25/2015 10:44:21 AM